Dual antiplatelet therapy for secondary prevention of coronary artery disease.

ABSTRACT: Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y₁₂ receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) compared with aspirin monotherapy, but at the expense of an increased risk of major bleeding. Nevertheless, the optimal duration of DAPT for secondary prevention of CAD remains uncertain, owing to the conflicting results of several large randomised trials. Among patients with stable CAD undergoing PCI with drug-eluting stents (DES), shorter durations of DAPT (3-6 months) were shown non-inferior to 12 or 24 months duration with respect to MACE, but reduced the rates of

SUBMITTER: Degrauwe S 

PROVIDER: S-EPMC5652612 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature